Thrombolytic therapy delivered intra-arterially rather than intravenously offers advantages in the treatment of ischemic stroke. However, the risk of symptomatic intracranial hemorrhage is increased, Northwestern University Medical School researchers report.
Dr. Mark J. Alberts and colleagues in Chicago, performed a meta-analysis of 27 studies that included 852 ischemic stroke patients who received intra-arterial thrombolytic therapy (IAT) and 100 controls. The results of their analysis appear in the November issue of Stroke: Journal of the American Heart Association.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!